Published in final edited form as:

Biopolymers. 2012 ; 98(5): 479–484. doi:10.1002/bip.22087.

Synthesis and Characterization of the 47-Residue Heterodimeric Antimicrobial Peptide Distinctin, Featuring Directed Disulfide Bridge Formation

Daniel G. Mullen^{†,§}, Raffaello Verardi[†], Fernando Porcelli[‡], Andrea Scaloni[#], George Barany[§], and Gianluigi Veglia^{†,§,*}

[†]Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA

[§]Department of Chemistry, University of Minnesota, Minneapolis, MN 55455, USA

[‡]Department for Innovation in Biological, Agro-Food and Forest Systems, DIBAF, University of Tuscia, Viterbo, Italy

[#]Proteomics & Mass Spectrometry Laboratory, ISPAAM, National Research Council, 80147 Naples, Italy

Abstract

Distinctin, a 47-residue heterodimeric peptide with potent antimicrobial activity, comprises two monomeric units linked covalently by a disulfide bond between Cys19 from the 22-residue A chain and Cys23 from the 25-residue B chain. Previous synthetic strategies involved assemblies of the two individual chains, followed by their co-oxidation to form the connecting disulfide bridge, and resulted in a mixture of three species: two homodimers and one heterodimer. Here, we report synthesis of exclusively heterodimeric distinctin, using recently developed tactics for directed disulfide bridge formation. Material prepared this way was characterized and found to be suitable for more detailed structural studies.

Keywords

Directed disulfide bridge formation; solid-phase synthesis; distinctin; antimicrobial peptides; solution NMR

Introduction

The increasing resistance of bacteria to antibiotics continues to be a serious global emergency for human health.^{2–6} To counteract this threat, researchers are seeking and studying novel alternatives, including antimicrobial agents that are unaffected by acquired resistance. In particular, antimicrobial peptides (AMPs) represent a viable approach to solve this problem.^{7–11} AMPs evolved as the first chemical defense mechanism of eukaryotic cells against bacteria, protozoa, fungi, and viruses; they show broad spectra of activity, and

*Corresponding Author: Gianluigi Veglia, 6-155 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, Phone: (612) 625-0758, Fax: (612) 625-2163, vegli001@umn.edu.

This article is dedicated to the late Michael and Kate Bárány, in tribute to their outstanding contributions to understanding the biochemistry and biophysics of peptides and proteins.

Supporting Information

Experimental procedures and analytical data for a non-labeled distinctin synthesis in which the A chain contains the activated Cys(Scm) residue for the directed disulfide bond formation step. Also, analytical HPLC traces for purified **3** and **4**.

represent potential chemical templates for developing antibiotics.^{12–17} Some AMPs are already in use to treat topical infections and have been commercialized by pharmaceutical companies.^{18–20}

Therefore, there is an increasing need to elucidate structural information on AMPs alone and during interactions in membrane environments, in order to better understand their mechanisms of action and to improve their design for potential therapeutic applications.

NMR spectroscopy has played a major role in research on AMPs in model membrane systems, and has inspired the development of new AMPs with increased potencies and selectivities by comparison to those that occur naturally.^{21–23} In addition, antimicrobial polymers have been designed and synthesized.^{24,25} Both liquid- and solid-state NMR have been applied.^{26–32} Solid-state NMR can give structural and dynamic information about the large-size complexes formed by lipid bilayers with peptides.^{27,33–36} Since the appropriate NMR techniques generally require milligram amounts of isotopically labeled peptides, there has been a significant effort to develop efficient procedures to obtain sufficient quantities of such peptides.

The present report focuses on distinctin, a 47-residue peptide originally extracted from *Phyllomedusa distincta*, a tree frog that lives in the forests of Brazil.³⁷ Distinctin preferentially interacts with negatively charged membranes and is active against Gram-positive and Gram-negative bacteria.^{38–40} According to recent findings on murine models, this peptide may be successfully used to treat topical infections and for embedding of medical devices.^{38,41} Structurally, distinctin consists of two linear chains of 22 (A chain) and 25 (B chain) residues, linked by a disulfide bridge that connects Cys19 of the A chain with Cys23 of the B chain (Figure 1). Previous synthetic schemes to create distinctin relied on air oxidation to form the crosslinking disulfide.^{39,40} Such methods suffer from the drawback that, in addition to the desired A-B heterodimeric distinctin, the A-A and B-B homodimers are also produced, in a molar ratio corresponding to the relative thermodynamic stabilities. Since all three species have similar HPLC retention times, the required purification step poses difficulties. Furthermore, non-selective air oxidation results in substantial diversion of material into undesired homodimeric by-products.

In contrast, we report here the chemical synthesis of distinctin by using a directed disulfide synthetic strategy that creates *only* the wanted heterodimeric product. Our overall strategy, and the specific tactics to implement it, allows for the efficient and cost-effective production of material that incorporates stable isotopic labels at discrete positions along the polypeptide chains, as is needed for conformational studies and investigations on the interactions between distinctin and lipid membranes by solid-state NMR spectroscopy.³⁶

Materials and Methods

General

All solvents were of HPLC grade. DIEA and TFA were of Sequalog/peptide synthesis grade from Fisher. Fmoc amino acids, HBTU, and HOBt were from AnaSpec. Preloaded Fmoc-AA-PEG-PS resins were purchased from Applied Biosystems. Isotopically labeled amino acids with *N*-Fmoc protection were from Cambridge Isotopes. All other reagents were from Sigma-Aldrich. Analytical and preparative RP-HPLC was conducted with water and CH₃CN solvent mixtures, each containing 0.1% TFA on Vydac 218TP54 C18 columns, 4.6 mm × 250 mm, 5.0 μ particles.

Peptide synthesis

SPPS of distinctin chains—Linear sequences were assembled on PEG-PS resins, with HBTU/DIEA as the coupling reagent, on a CEM Liberty peptide synthesizer with the default instrument Fmoc-based SPPS protocols. Isotopically labeled amino acids were double coupled using one equivalent of the Fmoc derivative for each cycle, mediated by the BOP reagent (1.0 eq.) and DIEA (2.0 eq.) as base. Subsequently, a single coupling with unlabeled Fmoc-amino acid 4.0 equiv) was run to react any remaining amine groups. For the chain that contained the isotopic labels, FmocCys(Trt) was used, while FmocCys(Acm) was incorporated into the unlabeled chain. The *N*-terminal Fmoc group was removed in the last instrument cycle.

Distinctin A chain containing Cys(Scm) (3)—To convert Cys(Acm) to Cys(Scm) on-resin, the peptide-resin (220 mg, 25 μ mol) was first swollen by extensive washing in CH_2Cl_2 . After the peptide-resin was suspended in CH_2Cl_2 (4 mL), neat methoxycarbonylsulfonyl chloride (3.0 μ L, 33 μ mol) was added, and the mixture was shaken for 3 h. The peptide-resin was then washed with CH_2Cl_2 (3×5 mL) and dried. The peptide was cleaved from the resin with freshly prepared reagent K [TFA–phenol–thioanisole–water–ethanedithiol (82.5:5:5:5:2.5 v/v)] (5 mL) under argon for 2 h, precipitated with ether (80 mL), and centrifuged to collect a pellet which was washed twice with ether. The crude peptide was dissolved in 0.1% aqueous TFA (20 mL), filtered, and purified by RP-HPLC. Yield: 12.1 mg (18%); T_r = 43 min; purity by RP-HPLC: 98%; deconvoluted ESI-MS: calculated mass 2615.4, observed mass 2615.4.

Distinctin B chain containing ^{15}N , ^{13}C -G5, ^{15}N -L6, ^{15}N -Y12, ^{15}N -L13 (4)—The peptide was cleaved from the resin with freshly prepared reagent K (5 mL) under argon for 3 h, precipitated with ether (80 mL), and centrifuged to form a pellet which was washed twice with ether. The crude peptide was dissolved in 0.1% aqueous TFA, filtered, and purified by RP-HPLC. Yield: 8.0 mg (9%); T_r = 40 min; purity by RP-HPLC: 95%; deconvoluted ESI-MS: calculated mass 2957.7, observed mass 2956.5.

Distinctin (5) by directed disulfide formation—The peptides were dissolved in 0.1% aqueous TFA at 1.0 mg/mL: [A chain] = 0.38 mM, [B chain] = 0.34 mM. $\text{Zn}(\text{OAc})_2$ dihydrate (3.0 mg, 13.5 μ mol, 5.0 equiv) was added to the B chain solution (8.0 mL, 2.7 μ mol), followed by the A chain solution (7.4 mL, 2.8 μ mol, 1.05 equiv); at this point, the homogeneous solution had a pH value of about 2. To start the reaction, 0.10 M acetate buffer (pH = 5.0, 1.0 mL) was added, and the pH of the reaction was adjusted into the range of 5.0–5.5 by careful dropwise addition of 1.0 N aqueous NaOH. The reaction was monitored by HPLC and judged to be complete within 1 h (Figure 2). The pH was then lowered into the range of 2–3 by addition of neat TFA, the reaction was filtered, and purification by RP-HPLC followed. Yield: 6.7 mg (45%); T_r = 43 min; purity by RP-HPLC: 92%; deconvoluted ESI-MS: calculated mass 5484.6, observed mass 5483.4.

Results and Discussion

We report here a directed disulfide synthesis strategy for the unambiguous and cost-effective production of heterodimeric distinctin molecules needed for NMR structural investigations. The application of directed methods to the peptide field dates to independent pioneering work of Kamber and Hiskey^{42,43} in the 1970s, and the overall principles and practices have been reviewed several times.^{44–46} Our preferred method of directed disulfide formation is to react two chains, the first containing a free cysteine thiol, and the second containing an activated Cys(Scm) residue, with one another in solution.^{47–50} In turn, we have found that the most robust and effective way to introduce the needed Cys(Scm) activation is to first

carry out solid-phase peptide synthesis (SPPS) for assembly of a chain that incorporates a Cys(Acm) residue, and then treating the completed peptide-resin with methoxycarbonylsulfonyl chloride to effect the Acm to Scm transformation (Scheme 1).^{49,51} This procedure has several advantages, including (i) potential side reactions such as sulfonylation of Tyr or His residues^{52–54} are avoided, because the peptide-resin is still globally protected at this stage; (ii) reaction stoichiometry is much easier to control during on-resin conversion, with respect to corresponding reactions in solution; and (iii) an intermediate purification step for isolation of the Cys(Scm)-containing peptide is no longer necessary, thus increasing the overall yield. The Scm group is stable throughout the standard acid/scavenger conditions used to release peptides from the support after SPPS, as well as during RP-HPLC purification. Moreover, peptides that contain a Cys(Scm) residue can be readily lyophilized and then stored at 0 °C for several weeks. For the synthetic work reported here that is directed towards distinctin, we have found that on-resin conversion of Cys(Acm) to Cys(Scm) worked equally well on either the A or B chains (data not shown); we choose to install the Cys(Scm) residue in whatever chain did not contain isotopic labels. Even though the Cys(Acm) residues that were to be converted in each case occur rather close to the respective C-termini in the sequences of greater than 20 residues, and one might be concerned a priori with hypothetical accessibility problems, this turned out to not be an issue in the actual practice.

In previous work, we found that further transformations of the Cys(Scm) group on full length peptides while still attached to the solid support, be they reduction with DTT or thiolytic displacement, gave varying results that seemed to depend on the location of the Cys(Scm) group in the sequence⁵¹. Thus, we elected to carry out the directed disulfide reaction in solution, where it can be monitored readily by RP-HPLC. In our experience, the solution directed disulfide formation step (Scheme 2) is best conducted under mildly acidic conditions with Zn²⁺ catalysis,⁵⁰ building on a precedent of Naider for alkylation of cysteine-containing peptides.⁵⁵ Under such acidic reaction conditions, unwanted side reactions such as air oxidation of chains (leading to homodimers) and disulfide exchange (scrambling of chains) are minimized or avoided entirely. The reaction of the Cys(Scm)-containing A chain (**3**) with the isotopically labeled B chain (**4**) was observed to proceed cleanly and with good kinetics in the pH range of 5.0 to 5.5, as established by an acetate buffer (Figure 2, Panel A). Distinctin (**5**) was the major product formed, and the reaction reached completion without further side product formation once the limiting reagent, the Cys(Scm)-containing A chain, was consumed. Because primarily **5** was produced in this reaction, with negligible levels of the two possible symmetrical disulfide-linked homodimers, RP-HPLC purification was straightforward (Figure 2, Panel B).

The synthetic strategy reported here is particularly conducive to the production of materials required for NMR studies. In order to conserve expensive ¹³C and/or ¹⁵N-labeled amino acids during chain assembly by stepwise SPPS, the appropriate Fmoc-amino acids were double coupled on a Liberty microwave synthesizer by using only one equivalent per cycle. A third coupling reaction followed with unlabeled Fmoc-amino acid was performed, so that acylation would go to completion, thereby preventing the formation of deletion peptides missing a residue at those positions that were to be labeled. When using this plan for the synthesis of the distinctin B chain, where four residues were labeled, we found upon electrospray mass spectrometry that a mass that was lower by about one atomic mass unit was reported for the product. This result means that incorporation of labels in each position was not quite quantitative. However, the ¹H-¹⁵N HSQC NMR spectrum of the purified distinctin product showed four distinct alpha cross peaks of approximate equal intensity (Figure 3). This result validates our overall strategy, which will now allow us to move forward with planned solid-state NMR experiments.

Conclusions

We report here a new synthesis for the antimicrobial peptide distinctin that features directed disulfide bridge formation. Unlike the previous synthetic method that generated a statistical mixture of homodimers along with desired heterodimer, our scheme makes possible the ready isolation of milligram quantities of pure distinctin, including variants with site-specific incorporation of isotopic labeled residues. Synthetic distinctin containing several ^{15}N -amino acids was characterized by NMR. A high-quality $[^1\text{H}-^{15}\text{N}]$ -HSQC spectrum was obtained, indicative of a well-folded polypeptide. Our overall synthetic process is straightforward, economical, and likely generalizable to the synthesis of other unsymmetrical disulfide-containing molecules of both peptidic and non-peptidic nature. Our laboratory is now poised to address further structural characterization of distinctin by solution and solid-state NMR, including studies of how the peptide interacts with membrane-mimetic systems.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by NIH grant GM 64742 to G.V.

Abbreviations

Acm	acetamidomethyl
Boc	<i>tert</i> -butoxycarbonyl
BOP	(benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate
<i>t</i>-Bu	<i>tert</i> -butyl
DIEA	diisopropylethylamine
DMF	<i>N,N</i> -dimethylformamide
DTT	dithiothreitol
ESI-MS	electrospray ionization mass spectrometry
Fmoc	9-fluorenylmethoxycarbonyl
HBTU	<i>O</i> -benzotriazole- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate
HOBt	1-hydroxybenzotriazole
OAc	acetate
Pbf	2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
PEG	polyethylene glycol
PEG-PS	polyethylene glycol–polystyrene graft copolymer resin support
reagent K	¹ TFA–phenol–thioanisole–water–ethanedithiol (82.5:5:5:5:2.5 v/v)
RP-HPLC	reversed-phase high pressure liquid chromatography
Scm	<i>S</i> -carbomethoxysulfonyl
SPPS	solid-phase peptide synthesis

TFA	trifluoroacetic acid
Trt	trityl

References

- King DS, Fields CG, Fields GB. *Int J Pept Protein Res.* 1990; 36:255–266. [PubMed: 2279849]
- Rubinchik E, Schneider T, Elliott M, Scott WR, Pan J, Anklin C, Yang H, Dugourd D, Muller A, Gries K, Straus SK, Sahl HG, Hancock RE. *Antimicrob Agents Chemother.* 2011
- Paterson DL. *Curr Opin Pharmacol.* 2006; 6:486–490. [PubMed: 16904377]
- Ho J, Tambyah PA, Paterson DL. *Curr Opin Infect Dis.* 2010; 23:546–553. [PubMed: 20802331]
- Giamarellou H, Poulakou G. *Drugs.* 2009; 69:1879–1901. [PubMed: 19747006]
- Giamarellou H. *Int J Antimicrob Agents.* 2010; 36(Suppl 2):S50–54. [PubMed: 21129924]
- Wu G, Li X, Fan X, Wu H, Wang S, Shen Z, Xi T. *Peptides.* 2011
- Venugopal D, Klapper D, Srouji AH, Bhonsle JB, Borschel R, Mueller A, Russell AL, Williams BC, Hicks RP. *Bioorg Med Chem.* 2010; 18:5137–5147. [PubMed: 20558071]
- Mechkarska M, Ahmed E, Coquet L, Leprince J, Jouenne T, Vaudry H, King JD, Conlon JM. *Comp Biochem Physiol C Toxicol Pharmacol.* 2010; 152:467–472. [PubMed: 20656059]
- Bommarius B, Kalman D. *IDrugs.* 2009; 12:376–380. [PubMed: 19517318]
- Abbanat D, Morrow B, Bush K. *Curr Opin Pharmacol.* 2008; 8:582–592. [PubMed: 18761107]
- Hata TR, Gallo RL. *Semin Cutan Med Surg.* 2008; 27:144–150. [PubMed: 18620136]
- Izadpanah A, Gallo RL. *J Am Acad Dermatol.* 2005; 52:381–390. quiz 391–382. [PubMed: 15761415]
- Lai Y, Gallo RL. *Trends Immunol.* 2009; 30:131–141. [PubMed: 19217824]
- Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. *J Immunol.* 2004; 172:3070–3077. [PubMed: 14978112]
- Jenssen H, Hamill P, Hancock RE. *Clin Microbiol Rev.* 2006; 19:491–511. [PubMed: 16847082]
- Schitteck B, Paulmann M, Senyurek I, Steffen H. *Infect Disord Drug Targets.* 2008; 8:135–143. [PubMed: 18782030]
- Brogden KA. *Nat Rev Microbiol.* 2005; 3:238–250. [PubMed: 15703760]
- Gordon YJ, Romanowski EG, McDermott AM. *Curr Eye Res.* 2005; 30:505–515. [PubMed: 16020284]
- Marr AK, Gooderham WJ, Hancock RE. *Curr Opin Pharmacol.* 2006; 6:468–472. [PubMed: 16890021]
- Avrahami D, Oren Z, Shai Y. *Biochemistry.* 2001; 40:12591–12603. [PubMed: 11601983]
- Bechinger B. *Adv Exp Med Biol.* 2010; 677:24–30. [PubMed: 20687478]
- Hong J, Oren Z, Shai Y. *Biochemistry.* 1999; 38:16963–16973. [PubMed: 10606532]
- Mensa B, Kim YH, Choi S, Scott R, Caputo GA, DeGrado WF. *Antimicrob Agents Chemother.* 2011; 55:5043–5053. [PubMed: 21844313]
- Tew GN, Scott RW, Klein ML, DeGrado WF. *Acc Chem Res.* 2009; 43:30–39. [PubMed: 19813703]
- Porcelli F, Verardi R, Shi L, Henzler-Wildman KA, Ramamoorthy A, Veglia G. *Biochemistry.* 2008; 47:5565–5572. [PubMed: 18439024]
- Bechinger B, Gierasch LM, Montal M, Zasloff M, Opella SJ. *Solid State Nucl Magn Reson.* 1996; 7:185–191. [PubMed: 9050156]
- Georgescu J, Munhoz VH, Bechinger B. *Biophys J.* 2010; 99:2507–2515. [PubMed: 20959091]
- Mascioni A, Porcelli F, Ilangoan U, Ramamoorthy A, Veglia G. *Biopolymers.* 2003; 69:29–41. [PubMed: 12717720]
- Porcelli F, Buck B, Lee DK, Hallock KJ, Ramamoorthy A, Veglia G. *J Biol Chem.* 2004; 279:45815–45823. [PubMed: 15292173]

31. Porcelli F, Buck-Koehntop BA, Thennarasu S, Ramamoorthy A, Veglia G. *Biochemistry*. 2006; 45:5793–5799. [PubMed: 16669623]
32. Epand RF, Maloy L, Ramamoorthy A, Epand RM. *Biophys J*. 2010; 98:2564–2573. [PubMed: 20513400]
33. Aisenbrey C, Bertani P, Bechinger B. *Methods Mol Biol*. 2010; 618:209–233. [PubMed: 20094867]
34. Gehman JD, Luc F, Hall K, Lee TH, Boland MP, Pukala TL, Bowie JH, Aguilar MI, Separovic F. *Biochemistry*. 2008; 47:8557–8565. [PubMed: 18652483]
35. Lam YH, Hung A, Norton RS, Separovic F, Watts A. *Proteins*. 78:858–872. [PubMed: 19847922]
36. Verardi R, Traaseth NJ, Shi L, Porcelli F, Monfregola L, De Luca S, Amodeo P, Veglia G, Scaloni A. *Biochim Biophys Acta*. 2011; 1808:34–40. [PubMed: 20719234]
37. Batista CV, Scaloni A, Rigden DJ, Silva LR, Rodrigues Romero A, Dukor R, Sebben A, Talamo F, Bloch C. *FEBS Lett*. 2001; 494:85–89. [PubMed: 11297740]
38. Cirioni O, Ghiselli R, Orlando F, Silvestri C, De Luca S, Salzano AM, Mocchegiani F, Saba V, Scalise G, Scaloni A, Giacometti A. *Crit Care Med*. 2008; 36:2629–2633. [PubMed: 18679116]
39. Raimondo D, Andreotti G, Saint N, Amodeo P, Renzone G, Sanseverino M, Zocchi I, Molle G, Motta A, Scaloni A. *Proc Natl Acad Sci U S A*. 2005; 102:6309–6314. [PubMed: 15840728]
40. Resende JM, Moraes CM, Munhoz VH, Aisenbrey C, Verly RM, Bertani P, Cesar A, Pilo-Veloso D, Bechinger B. *Proc Natl Acad Sci U S A*. 2009; 106:16639–16644. [PubMed: 19805350]
41. Giacometti A, Cirioni O, Ghiselli R, Orlando F, Silvestri C, Renzone G, Testa I, Mocchegiani F, Della Vittoria A, Saba V, Scaloni A, Scalise G. *J Biomed Mater Res A*. 2007; 81:233–239. [PubMed: 17120214]
42. Kamber B. *Helv Chim Acta*. 1973; 56:1370–1381. [PubMed: 4741275]
43. Hiskey RG, Muthukumaraswamy N, Vunnam RR. *J Org Chem*. 1975; 40:950–953. [PubMed: 1133637]
44. Andreu D, Albericio F, Sole NA, Munson MC, Ferrer M, Barany G. *Methods Mol Biol*. 1994; 35:91–169. [PubMed: 7894611]
45. Annis I, Hargittai B, Barany G. *Methods Enzymol*. 1997; 289:198–221. [PubMed: 9353723]
46. Akaji, K.; Kiso, Y. In *Synthesis of Peptides and Peptidomimetics*. Goodman, M.; Felix, A.; Moroder, L.; Toniolo, C., editors. Georg Thieme Verlag Stuttgart; New York: 2004.
47. Chen L, Bauerova H, Slaninova J, Barany G. *Pept Res*. 1996; 9:114–121. [PubMed: 8875590]
48. Chen L, Golser R, Machova A, Slaninova J, Barany G. *J Med Chem*. 1999; 42:5002–5009. [PubMed: 10585209]
49. Chen L, Zoulikova I, Slaninova J, Barany G. *J Med Chem*. 1997; 40:864–876. [PubMed: 9083475]
50. Wollack JW, Zeliadt NA, Mullen DG, Amundson G, Geier S, Falkum S, Wattenberg EV, Barany G, Distefano MD. *J Am Chem Soc*. 2009; 131:7293–7303. [PubMed: 19425596]
51. Mullen Daniel G, Weigel B, Barany G, Distefano Mark D. *J Pept Sci*. 2010; 16:219–222. [PubMed: 20401923]
52. Kamber B, Hartmann A, Eisler K, Riniker B, Rink H, Sieber P, Rittel W. *Helv Chim Acta*. 1980; 63:899–915.
53. Scoffone E, Fontana A, Rocchi R. *Biochemistry*. 1968; 7:971–979. [PubMed: 4297965]
54. Buku A, Altmann R, Wieland T. *Justus Liebigs Annalen der Chemie*. 1976:417–431.
55. Naider FR, Becker JM. *Biopolymers*. 1997; 43:3–14. [PubMed: 9174408]

Figure 1. Primary structure and disulfide bridging of distinctin. Both *N*-termini are amino groups, and both *C*-termini are carboxyl groups.

Figure 2.

Panel A. RP-HPLC monitoring of directed disulfide formation reaction (Scheme 2). Red trace: initial mixture of the reacting peptides at pH ~ 2, before the pH was adjusted to initiate the reaction. Note starting **3** and **4**. Black trace: peptide mixture after 1 h of reaction following pH adjustment to a value of 5.3; chromatogram shows formation of **5** and complete consumption of limiting **3**. Panel B. RP-HPLC of distinctin (**5**), after purification. All chromatograms involve a gradient from 10% to 50% B, over 40 min., flow 1.0 mL/min.

Figure 3. $[^1\text{H}-^{15}\text{N}]$ -HSQC spectrum of purified distinctin in aqueous buffer. The sample contained the following isotopic labels in the B chain: ^{15}N , ^{13}C -G5, ^{15}N -L6, ^{15}N -Y12, and ^{15}N -L13. All of the expected resonances appeared in the peptide fingerprint.

Scheme 1.

On-resin conversion of Cys(Acm) to Cys(Scm) in protected distinctin A-chain resin (*N*-terminus free from Fmoc removal step, conventional Wang-type handle), and subsequent cleavage from the resin with Reagent K.

Scheme 2.

Directed disulfide formation strategy for synthesis of distinctin, as catalyzed by Zn(OAc)₂ at pH 5.0 – 5.5.